{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:40:09Z","timestamp":1756320009153,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,12]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>We report two cases of anaplastic thyroid cancer (ATC) which had a very good response to a treatment with lenvatinib at 14 mg. A 73-year-old man with ATC stage IVB was operated on, undergoing a near-total thyroidectomy, and the pathological remnant tissue showed a quick and partial response to treatment with the drug. The patient had a single metastasis in the brain after 9 months, but then died due to bronchopneumonia after undergoing a neurosurgical intervention for the complete removal of the lesion. A 74-year-old woman with ATC stage IV was operated on, undergoing a near-total thyroidectomy after a neoadjuvant treatment with the drug, that was continued after surgical treatment. She had a partial remission of the local disease and of distant metastasis, which lasted for 14 months. She then died 4 months later due to cancer progression. Lenvatinib at 14 mg appears to be effective, fast and well tolerated.<\/jats:p>","DOI":"10.1136\/bcr-2020-236934","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T18:18:21Z","timestamp":1608661101000},"page":"e236934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-7178","authenticated-orcid":false,"given":"Daniele","family":"Barbaro","sequence":"first","affiliation":[{"name":"Department of Medicine, UO Endocrinology, USL North West Tuscany, General Hospital of Livorno, Livorno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Lapi","sequence":"additional","affiliation":[{"name":"Department of Surgery, UO Pathology, USL North West Tuscany Office in Livorno, Livorno, Toscana, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Viacava","sequence":"additional","affiliation":[{"name":"Department of Surgery, UO Pathology, USL North West Tuscany Office in Livorno, Livorno, Toscana, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liborio","family":"Torregrossa","sequence":"additional","affiliation":[{"name":"Deparment of Surgery, UO Pathology, University of Pisa, Pisa, Toscana, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"doi-asserted-by":"publisher","key":"2025082711054338000_13.12.e236934.1","DOI":"10.1089\/thy.2012.0302"},{"key":"2025082711054338000_13.12.e236934.2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland Surg"},{"doi-asserted-by":"publisher","key":"2025082711054338000_13.12.e236934.3","DOI":"10.1056\/NEJMoa1406470"},{"key":"2025082711054338000_13.12.e236934.4","first-page":"138","article-title":"Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer","volume":"12","author":"Iwasaki","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"2025082711054338000_13.12.e236934.5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"2025082711054338000_13.12.e236934.6","first-page":"7271","article-title":"Lenvatinib as a novel treatment for anaplastic thyroid cancer: a retrospective study","volume":"16","author":"Iwasaki","year":"2018","journal-title":"Oncol Lett"},{"key":"2025082711054338000_13.12.e236934.7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2018-0557","article-title":"A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer","volume":"15","author":"Takahashi","year":"2019","journal-title":"Future Oncol"},{"key":"2025082711054338000_13.12.e236934.8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/thy.2016.0627","article-title":"Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer","volume":"27","author":"I\u00f1iguez-Ariza","year":"2017","journal-title":"Thyroid"},{"key":"2025082711054338000_13.12.e236934.9","first-page":"16","article-title":"Efficacy of lenvatinib in a patient with anaplastic thyroid cancer","volume":"2017","author":"Oishi","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"doi-asserted-by":"publisher","key":"2025082711054338000_13.12.e236934.10","DOI":"10.1158\/1535-7163.MCT-09-0663"},{"key":"2025082711054338000_13.12.e236934.11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/1878-0261.12076","article-title":"Dovitinib enhances temozolomide efficacy in glioblastoma cells","volume":"11","author":"Thanasupawat","year":"2017","journal-title":"Mol Oncol"},{"doi-asserted-by":"publisher","key":"2025082711054338000_13.12.e236934.12","DOI":"10.1124\/jpet.117.246116"},{"key":"2025082711054338000_13.12.e236934.13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11095-014-1609-7","article-title":"Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1)","volume":"32","author":"Kort","year":"2015","journal-title":"Pharm Res"},{"key":"2025082711054338000_13.12.e236934.14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","article-title":"Association of lenvatinib Trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer","volume":"36","author":"Nagahama","year":"2019","journal-title":"Med Oncol"},{"key":"2025082711054338000_13.12.e236934.15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"doi-asserted-by":"publisher","key":"2025082711054338000_13.12.e236934.16","DOI":"10.1124\/dmd.111.043281"},{"key":"2025082711054338000_13.12.e236934.17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fendo.2018.00764","article-title":"Antineoplastic effect of lenvatinib and vandetanib in primary anaplastic thyroid cancer cells obtained from biopsy or fine needle aspiration","volume":"18","author":"Ferrari","year":"2018","journal-title":"Front Endocrinol"},{"key":"2025082711054338000_13.12.e236934.18","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-236934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:05:52Z","timestamp":1756317952000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-236934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-236934"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-236934","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}